Chief, Classical Hematology Service
University of Miami
Miami, Florida, United States
Dr. Soff’s career focus has been on the complex interrelationship and interactions of blood vessels, the constituents of the blood coagulation system, and cancer. Beyond simply studying why patients with cancer are prone to thrombosis, he studies how cancers utilize the coagulation system to enhance primary and metastatic growth. He has conducted numerous clinical and translational studies in this area.
As Chief of the Classical Hematology Service at University of Miami Health System/Sylvester Comprehensive Cancer Center, his focus has been on the clinical and translational sciences of thrombosis and thrombocytopenia cancer. He has published a number of practice-changing studies on Cancer-Associated Thrombosis (CAT) and Chemotherapy-Induced Thrombocytopenia (CIT). He has studied and reported on the safety and efficacy of the new Direct Oral Anticoagulant (DOAC) rivaroxaban as an anticoagulant in cancer patients and validated an anticoagulation dosing algorithm when cancer patients have both CAT and thrombocytopenia. Dr. Soff has published on safe and effective use of pre-operative anticoagulation to reduce the risk of perioperative thrombosis.
His current research focus is to identify and characterize biomarkers of coagulation, platelet activation, and vascular injury that may elucidate the pathways that cancers coopt to facilitate primary and metastatic growth, which may provide key clinical benefit as prognostic markers, and possibly serve as novel targets for cancer-directed therapy.
Education has always been a major focus of his academic career. He has mentored many students, residents, and fellows.
SSC 04.8 - ISTH Guidance: Chemotherapy induced thrombocytopenia
Saturday, June 24, 2023
15:45 – 16:00 ET